MAP2K7 and colorectal cancer: Motivated by the results of a phase III BEACON trial that demonstrated a triple drug combination in BRAFmut colorectal cancer significantly increased the response rate and the median overall survival with well-tolerated toxicity [33], we adapted this approach and designed a treatment against BRAF, MEK, and EGFR in our tumor model.